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ORIGINAL ARTICLE
A DNA methylation biomarker of alcohol consumption
C Liu1,2,3,55, RE Marioni4,5,6,55, ÅK Hedman7,55, L Pfeiffer8,9,55, P-C Tsai10,55, LM Reynolds11,55, AC Just12,55, Q Duan13,55, CG Boer14,55,
T Tanaka15,55, CE Elks16, S Aslibekyan17, JA Brody18, B Kühnel8,9, C Herder19,20, LM Almli21, D Zhi22, Y Wang23, T Huan1,2, C Yao1,2,
MM Mendelson1,2, R Joehanes1,2,24, L Liang25, S-A Love23, W Guan26, S Shah6,27, AF McRae6,27, A Kretschmer8,9, H Prokisch28,29,
K Strauch30,31, A Peters8,9,32, PM Visscher4,6,27, NR Wray6,27, X Guo33, KL Wiggins18, AK Smith21, EB Binder34, KJ Ressler35, MR Irvin17,
DM Absher36, D Hernandez37, L Ferrucci15, S Bandinelli38, K Lohman11, J Ding39, L Trevisi40, S Gustafsson7, JH Sandling41,42, L Stolk14,
AG Uitterlinden14,43, I Yet10, JE Castillo-Fernandez10, TD Spector10, JD Schwartz44, P Vokonas45, L Lind46, Y Li47, M Fornage48,
DK Arnett49, NJ Wareham16, N Sotoodehnia18, KK Ong16, JBJ van Meurs14, KN Conneely50, AA Baccarelli51, IJ Deary4,52, JT Bell10,
KE North23,56, Y Liu11,56, M Waldenberger8,9,56, SJ London53,56, E Ingelsson7,54,56 and D Levy1,2,56
The lack of reliable measures of alcohol intake is a major obstacle to the diagnosis and treatment of alcohol-related diseases.
Epigenetic modifications such as DNA methylation may provide novel biomarkers of alcohol use. To examine this possibility, we
performed an epigenome-wide association study of methylation of cytosine-phosphate-guanine dinucleotide (CpG) sites in relation
to alcohol intake in 13 population-based cohorts (ntotal = 13 317; 54% women; mean age across cohorts 42–76 years) using whole
blood (9643 European and 2423 African ancestries) or monocyte-derived DNA (588 European, 263 African and 400 Hispanic
ancestry) samples. We performed meta-analysis and variable selection in whole-blood samples of people of European ancestry
(n= 6926) and identified 144 CpGs that provided substantial discrimination (area under the curve = 0.90–0.99) for current heavy
alcohol intake (⩾ 42 g per day in men and ⩾ 28 g per day in women) in four replication cohorts. The ancestry-stratified
meta-analysis in whole blood identified 328 (9643 European ancestry samples) and 165 (2423 African ancestry samples)
alcohol-related CpGs at Bonferroni-adjusted Po1 × 10− 7. Analysis of the monocyte-derived DNA (n= 1251) identified 62
alcohol-related CpGs at Po1 × 10-7. In whole-blood samples of people of European ancestry, we detected differential methylation
in two neurotransmitter receptor genes, the γ-Aminobutyric acid-A receptor delta and γ-aminobutyric acid B receptor subunit 1; their
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differential methylation was associated with expression levels of a number of genes involved in immune function. In conclusion, we
have identified a robust alcohol-related DNA methylation signature and shown the potential utility of DNA methylation as a
clinically useful diagnostic test to detect current heavy alcohol consumption.
Molecular Psychiatry (2018) 23, 422–433; doi:10.1038/mp.2016.192; published online 15 November 2016
INTRODUCTION
Each year, nearly 2.5 million deaths worldwide are attributable to
alcohol use.1 Most alcohol-attributable diseases and injuries occur
in people without a diagnosed alcohol use disorder.2–5 Research-
ers have attempted to develop laboratory tests to detect heavy
drinkers who are more reliable than self-reported alcohol intake
(e.g. alcohol screening questionnaires). In addition, a biomarker
would be useful in epidemiologic studies of health effects of
alcohol as an objective measure to supplement and validate self-
reported data. It could also prove useful in studies of other
exposures where careful adjustment for alcohol intake is needed.6
Several biochemical measurements, such as serum alanine
transaminase (ALT) and aspartate transaminase (AST) levels have
been used to assess heavy alcohol use. However, the discrimina-
tory ability of these biomarkers is far from ideal, with the area
under the curve (AUC) to predict heavy alcohol consumption
ranging from 0.21 to 0.67.7 The addition of four protein markers,
AT-rich interactive domain-containing protein 4B (ARID4B),
phosphatidylcholine-sterol acyltransferase (LCAT), hepatocyte
growth factor-like protein (MST1) and ADP-ribosylation factor 6
(ARL6), improved AUC values for the detection of heavy drinkers
to 0.73–0.86, leaving room for further improvement.7
Emerging evidence suggests that alcohol consumption influ-
ences epigenetic modifications,8–10 which in turn can affect gene
expression levels.8,11,12 Methylation of the cytosine position in
CpGs is among the best-characterized epigenetic modifications.13
To date, more than 20 studies have been conducted to identify
alcohol-related DNA methylation signatures. Most of these studies,
however, have focused on alcohol dependence in relation to
‘global’ methylation levels or preselected candidate genes14 and
only a few studies have used epigenome-wide approaches.15–18
The largest genome-wide study so far included about 700
individuals.16 To date, limited sample sizes have hindered the
search for a robust alcohol-related DNA methylation signature.
Hence, there is a need for a large-scale collaborative effort to
determine the association of alcohol consumption with DNA
methylation across the genome. Here we demonstrate that DNA
methylation can be used as a highly predictive blood biomarker to
detect heavy alcohol drinking. We also report meta-analysis results
from epigenome-wide association studies (EWAS) in up to 13 317
individuals from 13 cohorts in which DNA methylation was measured
in blood samples using the Infinium HumanMethylation450
BeadChip (Illumina, San Diego, CA, USA). Third, we determined
the genetic contributions to alcohol-related methylation
differences. Finally, we explored the functional implications of
alcohol-related differential methylation by testing its association
with gene expression in blood.
MATERIALS AND METHODS
Study population
This analysis included 13 317 participants from 13 population-based
prospective cohorts of the Cohorts for Heart and Aging Research in
Genomic Epidemiology Consortium plus (CHARGE+) Consortium. These
cohorts were sampled from free-living members of the community, but
they were all not required to be healthy nor were they selected based on
disease. During follow-up, some participants developed health conditions
such as cardiovascular diseases (CVDs) and cancer. About 54% of
participants were women and the average age was from 42 to 76 years
old across the cohorts (Table 1). The patterns of alcohol consumption
varied widely across the cohorts. For nine cohorts, fewer than one-third of
participants reported no current alcohol intake and for four cohorts more
than 50% of participants reported no current alcohol intake. The high
proportion of non-drinkers in these four cohorts is in line with other
studies of people of comparable age, birth cohort and gender mix. Heavy
drinkers, defined below, represented 2–17% of participants across studies
(Table 1). Informed consent for genetic studies was obtained from all
subjects. The protocol for each study was approved by the institutional
review board of each cohort.
Alcohol traits
Alcohol consumption was measured by self-administered questionnaires
or structured interview with a trained psychologist at the same period
when blood samples were obtained for DNA methylation quantification.
Alcohol consumption measured the total consumption of beer, wine and
spirits. For American cohorts, a drink was defined as 12 ounces of beer,
4–5 ounces of wine or 1.5 ounces of liquor, where one drink is equivalent
to ~ 14 g of ethanol. For European cohorts, a slightly different definition of
‘a drink’ and its conversion to grams of ethanol was used (Supplementary
Information: pp 14–16, 19–22 in Description of study samples). The
continuous exposure variable was defined as the average grams of ethanol
consumed per day (g per day) over the course of a year during the period
when the blood sample was collected for DNA methylation quantification.
The continuous variable was further categorized into four drinking
categories. ‘Non-drinkers’ were subjects with no alcohol consumption
(i.e., g per day = 0); ‘light drinkers’ were subjects who consumed 0og
per day⩽ 28 in men and 0og per day⩽ 14 in women; ‘at risk-drinkers’
were subjects who consumed 28og per dayo42 in men and 14og
per dayo28 in women; ‘heavy drinkers’ were subjects who consumed
⩾ 42 g per day in men and ⩾ 28 g per day in women.
To explore the effects of ‘former’ alcohol drinking on DNA methylation,
we examined alcohol consumption at prior examinations for all current
non-drinkers (n=693, see Table 1) in the Framingham Heart Study (FHS)
because information on prior drinking was not available in the majority of
other cohorts. We classified non-drinkers in FHS into ‘never’ drinkers and
‘former’ drinkers. ‘Never’ drinkers were individuals who self-reported no
alcohol consumption at any prior examination; ‘former’ drinkers were
individuals who reported alcohol consumption at any prior examination.
For ‘former’ drinkers, we calculated their alcohol consumption (‘g per day’)
at each prior examination.
DNA methylation quantification and quality control
DNA was extracted from whole-blood (n=9643 European (EA) and 2423
African ancestry (AA)) and CD14+ monocyte (n=1251 of mixed EA
(n=588), AA (n=263) and Hispanic ancestry (n= 400) samples (Table 1 and
Supplementary Information). Detailed information about DNA extraction,
bisulfite conversion, methylation profiling, normalization and quality
control (QC) procedures can be found in Supplementary Information.
Study samples were excluded from analysis if they had a missing rate of
41–5% across methylation probles; poor single nucleotide polymorphism
(SNP) matching compared with previous genotyping of the 65 SNPs
included on the methylation array; or sample outliers identified by
multidimensional scaling techniques. The methylation probes were
excluded if they were the 65 SNP probes, or probes that were previously
identified to map to multiple locations (n=29 233);19 had average
detection P40.01 (the detection P-value indicates the probe performance);
had an underlying SNP within 10 bp of that probe or if the minor allele
frequency (MAF) of the underlying SNP was 45% in the 1000 Genomes
Project data (n=15 178).19 After these filtering procedures, ~ 440 000 DNA
methylation probes remained for subsequent analyses.
Association between DNA methylation and alcohol intake
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Table 1. Characteristics of the study participants
Study N Men (%) Age (years), mean (s.d.) BMI mean (s.d.) Current smoking (%) g per day, Median
(min, max)
Non-drinkers (%) Light drinkers (%) At-risk drinkers (%) Heavy drinkers (%)
European ancestry whole blood (n = 9643)
CHS 185 84 (45) 76 (5) 27 (5) 16 (9) 0 (0, 99) 104 (56) 59 (32) 7 (4) 15 (8)
EPIC-Norfolk 1275 650 (51) 60 (9) 27 (4) 191 (15) 3 (0, 98) 271 (21) 865 (68) 79 (6) 60 (5)
FHS 2427 1095 (45) 66 (9) 28 (5) 304 (13) 4 (0, 181) 693 (29) 1260 (52) 280 (11) 194 (8)
InCHIANTI 499 225 (45) 63 (16) 27 (4) 94 (19) 8 (0, 161) 106 (21) 265 (53) 70 (14) 58 (12)
KORA F4 1797 877 (49) 60 (9) 28 (5) 262 (15) 7 (0, 150) 534 (29) 751 (42) 282 (16) 230 (13)
LBC1936 920 465 (51) 70 (1) 28 (4) 103 (11) 7 (0,158) 181 (20) 574 (62) 104 (11) 61 (7)
NAS 623 623 (100) 72 (7) 28 (4) 27 (4) 6 (0, 93) 148 (24) 385 (62) 52 (8) 38 (6)
PIVUS 818 412 (50) 70 (0.2) 27 (4) 75 (9.2) 6.7 (0, 61) 142 (17) 639 (78) 32 (4) 5 (1)
RS 502 241 (48) 58 (7) 27 (5) 137 (27) 14 (0, 88) 10 (2) 366 (73) 84 (17) 42 (8)
TwinsUK 597 0 (0) 56 (9) 27 (5) 57 (10) 2 (0,59) 189 (31) 375 (63) 22 (4) 11 (2)
African ancestry whole blood (n = 2423)
ARIC 2003 721 (36) 56 (6) 30 (6) 490 (24) 0 (0, 301) 1519 (76) 67 (3) 69 (3) 348 (17)
CHS 190 66 (35) 73 (5) 29 (5) 29 (15.3) 0 (0, 74) 123 (65) 61(32) 2 (1) 4 (2)
GTP 230 76 (33) 42 (12) 32 (8) 74 (39) 14 (0,143) 45 (20) 113 (49) NA 72 (31)
CD14+ monocytes (n= 1251)
MESA 1251 606 (48) 60 (9) 30 (6) 114 (9%) 8 (0, 191) 691 (55) 444 (36) 65 (5) 51 (4)
Abbreviations: ARIC, The Atherosclerosis Risk in Communities study; BMI, body mass index; CHS, The Cardiovascular Health Study; EPIC-Norfolk, The European Prospective Investigation into Cancer-Norfolk
study; FHS, The Framingham Heart Study; GTP, The Grady Trauma Project; KORA F4, The Cooperative Health Research in the Region of Augsburg study; InCHIANTI, Invecchiare in Chianti; LBC1936, The Lothian
Birth Cohort 1936; MESA, The Multi-Ethnic Study of Atherosclerosis; NAS, The Normative Aging Study; PIVUS, The Prospective Investigation of the Vasculature in Uppsala Seniors Study; RS, The Rotterdam Study;
TwinsUK, The TwinsUK Study. The drinking categories were defined based on grams of alcohol consumed per day (g per day): non-drinkers, g per day= 0; light drinkers, 0o–≤ 28 g per day in men and
0o–≤ 14 g per day in women; at-risk drinkers, 28o–o42 g per day in men and 14o–o28 g per day in women; and heavy drinkers, g per day ≥ 42 in men and ≥ 28 in women. The Monocyte samples
included mixed samples of European (47%), African (21%) and Hispanic (32%) ancestries.
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Clinical and laboratory phenotypes
Age, height and weight were measured using standard protocols
implemented at the time DNA samples were collected. Body mass index
(BMI) was calculated as weight (kg) per height (m) squared. Smoking was
determined by self-report. Current smokers were defined as smokers of at
least 1 cigarette per day over the course of a year at the time of blood
sample collection for methylation quantification.
In the FHS cohort, the serum AST and ALT levels were measured on
fasting morning samples using the kinetic method20 at the same
examination cycle when whole blood was obtained for DNA methylation
measurement. ALT and AST were set to 5 if their measured levels were
o5 U l− 1. An individual was defined as having CVD if he or she had
coronary heart disease, myocardial infarction, atherothrombotic infarction
of brain or congestive heart failure. A cancer phenotype was defined if the
person had any type of cancer. Both CVD and cancer phenotypes were
defined at the time of blood collection for measuring DNA methylation.
Statistical analysis
Epigenome-wide association studies. In each cohort, the primary EWAS
model used a DNA methylation β-value (the ratio of methylated probe
intensity divided by the sum of the methylation and unmethylated probe
intensity) as the outcome variable and the continuous alcohol trait
(g per day) as the predictor variable of interest. Because it has been shown
that many CpG sites are significantly associated with age,21 sex22 and
BMI,23 these three variables were adjusted for in EWAS analysis.
Furthermore, it has been known that DNA methylation profiling is
susceptible to batch effects24 and by white cell composition in whole
blood.25 Thus, ‘batch effects’ and ‘white cell blood counts’ were adjusted
for to minimize confounding effects that may result in spurious association.
To account for batch effects, ‘lab’, ‘experiment date’, ‘plate’, ‘row’ and
‘column’ were adjusted for in the analyses. The measured or imputed25
white blood cell counts for CD4 cells, CD8 cells, natural killer cells,
B cells and monocytes were adjusted for in the analyses. Surrogate
variables (to account for unknown confounders)26 or principal components
(estimated from genotypes to account for population stratification)27were
included in the EWAS model when applicable (pp 10, 11 and 15 of
Description of study samples in Supplementary Information). In the
secondary analysis, we used the categorical alcohol intake as the predictor
adjusting for the same covariates described above. The non-drinker
category was used as the reference group. We used a linear model in
unrelated individuals or a linear mixed model in family samples to account
for familial correlation in the association of DNA methylation and alcohol
consumption.
It is unclear if smoking confounds the relationship between alcohol
intake and DNA methylation or if smoking and alcohol intake are
associated with common CpGs. Therefore, we performed an additional
sensitivity analysis with and without current smoking status as a covariate
in drinker-only samples. We compared the change in the regression
coefficient for the continuous alcohol intake trait when including current
Whole blood DNA
European ancestry (n=9,643)
African ancestry (n=2,423)
CD14+ monocytes (n=1,251)
Study samplesDNA bisulfite conversion
Quality control
Methylation measured 
using the Infinium 
HumanMethylation450 
BeadChip
Genotypes: 1000g 
imputation; minor allele 
frequency > 0.05 and 
imputation quality>0.5
Primary: DNAm = g per day + age + sex + BMI + technical covariates + WBCs 
Secondary: DNAm = I (light/at-risk/heavy drinkers versus non-drinkers) + age + sex + BMI 
+ technical covariates +WBCs 
Gene expression (Affymetrix 
Human Exon Array ST 1.0 and 
Illumina Human HT-12 v3 ) 
Methylation analysis
Epigenome-wide association analysis in each cohort 
Other types of analyses
1. Association between alcohol-related CpGs and 
•
•
cis-SNPs within 100 kb 
mRNA levels of cis-genes within 1 Mb 
2. -Association between two CpGs in gamma
aminobutyric acid (GABA) receptor genes and 
genome-wide mRNA levels 
3. Gene Ontology analysis to evaluate the 
enrichment of genes in biological processes
Test the selected CpGs in the training 
cohort (FHS) and the replication cohorts 
(KORA F4, LBC1936, ARIC and MESA) for
1. Variance explained in the continuous 
alcohol consumption trait
2. ROC analysis-heavy drinkers versus 
non-drinkers/light drinkers 
Significance =P<1x10-7` 
Discovery meta-analysis  of whole 
blood samples of EA ancestry 
excluding LBC1936 and KORA F4
P<5x10-6
LASSO analysis in FHS (the training set) to
select CpGs to be used as a biomarker
1.
2.
Ancestry-specific meta-analysis of 
whole blood samples
Meta-analysis of pooled samples of 
whole blood and monocyte samples 
Biomarker analysis Analysis of methylation signature
Figure 1. Overview of the study design. ARIC, The Atherosclerosis Risk in Communities study; BMI, body mass index; DNAm, DNA methylation
value; FHS, the Framingham Heart Study; I (light/at-risk/heavy drinkers versus non-drinkers), the indicator variable for light drinkers versus
non-drinkers, at-risk drinkers versus non-drinkers and heavy drinkers versus non-drinkers; KORA F4, The Cooperative Health Research in the
Region of Augsburg study; LASSO, least absolute shrinkage and selection operator; LBC, The Lothian Birth Cohort; MESA, The Multi-Ethnic
Study of Atherosclerosis; WBCs, white blood cell counts.
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smoking in the model compared with the regression coefficient when
smoking was not included in the model using the following equation:
Δβalcoholsmk ¼ 100%  βalcoholsmk - βalcoholnosmkð Þ
We performed sensitivity tests in the FHS data to investigate if CVD and
cancer confounded the relationship between DNA methylation and
alcohol consumption. The sensitivity test compared the regression
coefficients and P-values between methylation and alcohol intake in a
EWAS model that did not adjust for CVD or cancer status to a second
model that adjusted for CVD or cancer status. Other covariates included
age, sex, BMI, batch effects and white blood cell counts.
DNA methylation as a biomarker in predicting alcohol
consumption
We performed the following four-step analyses to investigate if DNA
methylation can be used as a biomarker in discriminating alcohol
consumption categories (Figure 1).
Step 1: To establish independent replication cohorts, we split the whole-
blood DNA samples from 10 cohorts of (EA (n= 9643; Table 1) into separate
discovery and replication sets. The discovery set consisted of eight EA
cohorts (n= 6926), excluding the Lothian Birth Cohort 1936 (LBC1936) and
Cooperative Health Research in the Region of Augsburg (KORA F4) study
(Table 1). We performed a meta-analysis in the eight EA cohorts using an
inverse-variance weighted random-effects model and selected CpGs at a
relaxed threshold Po5 × 10− 6.
Step 2: To minimize overfitting and to explore which CpGs are more
important for including in a biomarker of alcohol consumption, we
performed least absolute shrinkage and selection operator (LASSO)
regression in the FHS cohort as a training set:
log g per dayþ 1ð Þ ¼
X
n¼1
ResidCpGþ ageþ sexþ BMI
In the above formula, all CpGs at Po5× 10− 6 were included simulta-
neously in the LASSO analysis. Because alcohol consumption was right
skewed and contained non-drinkers, the log-transformed alcohol con-
sumption (log (g per day+1)) was used as the outcome. To minimize
potential confounding effects in selecting a set of CpGs as a biomarker, we
obtained the residuals for each CpG in a linear regression model
(CpG= age+sex+BMI+batch effects+white blood cell counts). Here vari-
ables for ‘batch effects’ and ‘white blood cell counts’ were the same as the
variables used in EWAS analysis. In the LASSO analysis, we selected four
sets of CpGs using s= ‘lambda.min’, ‘lambda.1se’, 0.08 and 0.12. The
criterion s= ‘lambda.min’ selected the largest number of CpGs and s= 0.12
yielded the most parsimonious set of CpGs. We removed CpGs if they are
not on the Infinium MethylationEPIC BeadChip (Illumina), which will
replace the Illumina Infinium HumanMethylation450 BeadChip.
Step 3: In the FHS training set, we first estimated the proportion of
variance in continuous alcohol consumption explained by the selected
CpGs. The adjusted R2 was estimated for the ‘Null’ model log
(g per day + 1) = age+ sex +BMI and the ‘Full’ model log (g per day + 1) =P
n¼1
ResidCpG+ age+ sex + BMI. The proportion of variance explained by a
set of CpGs was the difference of adjusted R2 between the ‘Full’ and
‘Null’ models: adjR2CpGs ¼ adjR2ageþsexþBMIþCpGs - adjR2ageþsexþBMI.
Discrimination of heavy alcohol consumption from non-drinkers or light
drinkers was our main focus. Therefore, we generated receiver-operating
characteristic curves (ROC) in the FHS training cohort to evaluate the
performance of these four sets of CpGs in classifying current heavy
drinkers versus (1) non-drinkers, (2) light drinkers and (3) pooled
individuals of light or non-drinkers. In addition, we evaluated if these
CpGs can be used in classifying individuals in the following comparisons:
(4) heavy drinkers versus at-risk-drinkers; (5) at-risk drinkers versus non-
drinkers; (6) at-risk drinkers versus light drinkers; and (7) light drinkers
versus non-drinkers. In all comparison pairs, the former category was the
‘disease’ group and the latter was the ‘control’ group. In ROC analysis, the
expected probability of being ‘diseased’ was calculated using logistic
regression in which the ‘disease’ (1/0) was used as the outcome variable,
and age, sex and BMI without or with a set of CpGs (residuals) as
independent variables. Sensitivity, specificity and the AUC for classifying
‘diseased’ individuals versus ‘controls’ were calculated. We also performed
sensitivity tests to investigate the prediction performance from current
smoking, ALT and AST.
Step 4: We repeated the Step 3 analyses in two independent cohorts of
whole-blood-derived DNA samples in people of EA (LBC1936 and KORA F4)
for replication purposes. We also repeated the Step 3 analyses in whole-
blood-derived DNA samples of people of AA (the Atherosclerosis Risk in
Communities Study or ARIC) and in the monocyte-derived DNA samples
(the Multi-Ethnic Study of Atherosclerosis or MESA) for both replication and
generalization. The MESA samples included individuals of EA (n= 588), AA
(n=263) and Hispanic ancestry (n= 400). We used all 1251 individuals in
MESA to estimate the proportion of variance in alcohol consumption that
was explained by the CpGs, but only used the 588 individuals of EA for the
ROC analysis; there were too few heavy drinkers of AA or Hispanic ancestry
for meaningful analysis.
The R statistical software (https://www.r-project.org/) was used for all
analyses. Linear regression was performed using the function ‘lm’ for
unrelated samples and ‘lme’ for family samples to account for family
structure. LASSO was performed using the function ‘glenet’ in the ‘glenet’ R
package with the parameter α= 1 and 10-fold cross-validation to select
CpGs. The ROC analysis used the ‘pROC’ package with the ‘lme’ function for
logistic regression, and then the ‘predict’ function to predict the expected
probability, and finally the ‘roc’ function to estimate sensitivity and
specificity of a set of predictors for predicting ‘disease’ versus ‘control’
status.
Meta-analysis to identify DNA methylation signature
The inverse variance-weighted random-effects model28 was used in meta-
analysis because of the heterogeneity in levels of alcohol consumption and
population demographics (Table 1). The meta-analysis was performed in
ancestry-stratified whole-blood-derived DNA samples (n=9643 EA and
n= 2423 AA) and, secondarily, in combined transethnic samples of
whole-blood and monocyte-derived DNA (n=13 317). In the meta-analysis,
a CpG was further removed if it was missing in five or more studies or
its sample size was o20% of the total sample size. We used
Po0.05/440 000 ~ 1× 10− 7 to establish significance.
We reported alcohol-related CpGs (P⩽ 1 × 10− 7) in meta-analysis of
ancestry-stratified whole-blood-derived DNA samples and in monocyte-
derived DNA samples, and compared alcohol-related CpGs between
ancestries and between whole-blood and monocyte samples. We also
investigated the DNA methylation levels in several genes that were
previously reported to be associated with alcohol metabolism29,30 or
alcohol-related neurotransmission.31–34
DNA methylation in former and never drinkers
To investigate if DNA methylation signals differ between ‘former’ and
‘never’ drinkers, we performed three additional EWAS analyses with DNA
methylation as the outcome variable and three binary traits as the
independent variables (adjusting for age, sex, BMI, batch effects and white
blood cell counts) in the FHS data. The first analysis using the binary trait
‘never’ versus ‘former’ as the independent variable, and the other two the
binary traits ‘heavy’ versus ‘never’ or ‘heavy’ versus ‘former’ as the
independent variable. A linear mixed-effects model was used to account
for family structure.
Methylation quantitative trait loci analysis. Methylation quantitative trait
locus analysis (meQTLs) was performed in three cohorts: FHS (n= 2024),
KORA F4 (n=1799) and the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) study (n= 920). Genotyping, genotype imputation
and QC details are described in the Supplementary Information. Using data
imputed (allele dosage) to the 1000 Genomes (reference), we selected
cis-SNPs (defined as ± 100 kb) with imputation quality score 40.8 and
minor allele frequency ⩾ 0.05. The meQTL mapping was performed
between the significant alcohol-related CpGs (outcomes) and cis-SNPs
(predictors), adjusting for age, sex, BMI, batch effects and white blood
cell counts. The proportion of variance (r2) that can be explained by
cis-SNPs or meQTLs for a CpG was also calculated in association analysis.
We used a linear model in unrelated individuals or a linear mixed-effects
model in family samples to account for familial correlation in association
test between an SNP dosage and DNA methylation. Meta-analysis
used the inverse-variance weighted random-effects model. We used
Po0.05/n to establish significance, where n was the number of CpG–SNP
pairs tested.
Association analysis between methylation and gene expression
Gene expression profiling and QC in FHS (n=1924) and KORA F4 (n=707)
are detailed in the Supplementary Information. To perform the association
analysis, the FHS samples were divided into discovery (n=966) and
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replication (n=958) sets by independent pedigrees. In both FHS and KORA
F4 samples, residuals of gene expression levels (ResidGene) or CpG β-values
(ResidCpG) were obtained by adjusting for age, sex, BMI, batch effects and
white blood cell counts. Here batch effects and cell proportion differentials
(if calculated) were expression-specific or methylation-specific values. The
association analysis was then performed between ResidGene and ResidCpG.
A linear model was used in unrelated samples and a linear mixed model
was used in family data to account for family structure. The proportion of
variance in a transcript that was explained by a CpG was also calculated.
Because FHS and KORA F4 used different expression arrays, we only used
CpG–gene name pairs that could be matched between the two studies.
Therefore, we used the Z-score method35 for meta-analysis. We used
Po0.05/n to establish statistical significance, where n was the number of
CpG-gene transcript pairs tested.
Functional inference and pathway analysis
Genomic features of the alcohol-related CpGs. The genomic location of a
CpG provides functional insight into regulatory features.36 According to
the annotation ‘HumanMethylation450_15017482_v.1.2.csv’ provided by
Illumina, we compared the enrichment or depletion of several genomic
features, including CpG islands, CpG shores and shelves, enhancers, DNA
hypersensitivity sites and promoters in the set of alcohol-related CpGs
(Po1× 10− 7) compared with the background universe of all CpG probes
assessed on the microarray that passed QC. The difference in proportions
of a genomic feature was compared by the Fisher’s two-sided test.
Gene ontology enrichment analysis and functional inference. We per-
formed Gene Ontology (http://geneontology.org/page/go-enrichment-
analysis) enrichment analysis for the genes that were annotated to the
significant alcohol-related CpGs. We also examined the genes whose
expression levels were significantly associated with the significant alcohol-
related CpGs.
RESULTS
A methylation biomarker of alcohol consumption
The meta-analysis of the discovery set that included the whole-
blood-derived DNA of individuals of EA from eight cohorts
(n= 6926; Table 1) identified 361 CpGs at Po5− 10− 6. Of these
361 CpGs, 333 are on the new Infinium MethylationEPIC BeadChip.
Using the FHS cohort as the training set, we selected 5 (s= 0.12),
23 (s= 0.08), 78 (s= ‘lambda.1se’) and 144 (s= ‘lambda.min’) CpGs
out of the 333 CpGs with the LASSO regression (see Materials and
Methods). All CpGs in the smaller lists are subsets of the largest set
of 144 CpGs (s= ‘labmda.min’) (Supplementary Table 1). All
selected CpGs were available in MESA and ARIC. Five CpGs in the
144 set and one in the 78 CpG set were unavailable in KORA F4
and LBC1936 (Supplementary Table 1).
The most parsimonious set of 5 CpGs explained a substantial
proportion of interindividual variance in alcohol consumption in
KORA F4 (6.4%), LBC1936 (10.4%), ARIC (5.2%), MESA (9.9%) and
FHS (15.0%). The addition of more CpGs yielded larger proportions
of explained variance in alcohol consumption. The largest set (144
CpGs) explained 13.1 (KORA F4), 12.0 (LBC1936), 13.8 (ARIC), 13.1
(MESA) and 27.3% (FHS) of variance in alcohol consumption
(Table 2). Because the FHS was used as the training cohort to
select CpGs, the estimated variance values obtained in the FHS
were more optimistic compared with those obtained in the four
replication cohorts.
In ROC analysis of ‘disease’ versus ‘control’ status (see Materials
and Methods), including any CpGs in addition to clinical variables
(age, sex and BMI) (the ‘Full’ model) resulted in a larger AUC value
compared with the model with only clinical variables (the ‘Null’
model). The models with the two smaller sets of CpGs (5 CpGs and
23 CpGs) yielded good prediction (AUCFull 40.80) in all five
cohorts for discriminating heavy drinkers versus non-drinkers; the
models with the two larger sets of CpGs (78 CpGs and 144 CpGs)
gave good prediction (AUC40.80) in all five cohorts for
discriminating heavy drinkers versus non-drinkers/light drinkers/
at-risk drinkers, or in discriminating at-risk drinkers versus
non-drinkers (Figure 2 and Supplementary Figure 1). For example,
the addition of the 144 CpGs to the null model yielded a high AUC
for discriminating heavy drinkers versus non-drinkers (AUCFull =
0.90–0.99 compared with AUCNull = 0.63–0.80) and heavy drinkers
versus light drinkers (AUCFull = 0.85–0.99 compared to AUCNull =
0.53–0.61) across the five cohorts; the addition of 78 CpGs to the
null model yielded slightly lower AUC values compared with
addition of the 144 CpGs: AUCFull = 0.88–0.99 in discriminating
heavy drinkers versus non-drinkers and AUCFull = 0.82–0.96 in
discriminating heavy drinkers versus light drinkers. It is worth
noting that in discriminating heavy drinkers versus non-drinkers/
light drinkers, the performance of the 144 CpGs and 78 CpGs was
better in MESA and LBC1936 compared with that in FHS (the
training cohort); but the performance of these two sets of CpGs
was lower in KORA F4 and ARIC (Figure 2). Unavailability of a few
CpGs in LBC1936 did not seem to affect discrimination (Table 2
and Figure 2).
Current smoking explained a very small proportion of variance
in alcohol consumption. For example, the change in adjusted
R2 = 0.003 in FHS and 0.01 in MESA when current smoking was
included in the model in addition to age, sex and BMI. Similarly,
ALT or AST explained a small proportion of variance in alcohol
consumption in FHS: the change in adjusted R2 = 0.004 when
either ALS or AST was added to the null model. Therefore, neither
ALT nor AST was a good biomarker for alcohol consumption,
which was confirmed in ROC analysis: AUCNull+ALT or Null+AST = 0.67
when ALT or AST was added in the null model (AUCNull = 0.66) in
discriminating heavy drinkers versus non-drinkers in FHS.
Table 2. The proportion of variance in alcohol consumption
explained by DNA methylation
Study Variance explained (%)
Null 5 CpGs 23 CpGs 78 CpGs 144 CpGs
KORA F4 12.5 6.4 7.4 11.4 13.1
LBC1936 9.9 10.4 11.1 12.2 12.0
ARIC 20.0 5.2 6.0 12.4 13.8
MESA 11.6 9.9 10.5 11.7 13.1
FHS 7.8 15.0 18.9 24.6 27.3
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; BMI, body
mass index; CpG, cytosine-phosphate-guanine dinucleotide; FHS, Framing-
ham Heart Study; KORA F4, Cooperative Health Research in the Region of
Augsburg; LASSO, least absolute shrinkage and selection operator;
LBC1936, The Lothian Birth Cohort 1936; MESA, Multi-Ethnic Study of
Atherosclerosis. The meta-analysis using the whole-blood-derived DNA of
individuals of European ancestry from eight discovery cohorts (n= 6926,
see Materials and methods) excluding KORA F4 and LBC1936 identified 361
CpGs with Po5 × 10− 6. Of these 361 CpGs, 333 are on the new Infinium
MethylationEPIC BeadChip. Using the FHS data as the training set, we
selected 5 (s= 0.12), 23 (s= 0.08), 78 (s= ‘lambda.1se’) and 144 (s=
‘lambda.min’) CpGs with the LASSO regression (see Materials and
Methods). The testing cohorts included two cohorts of European ancestry
with the whole-blood-derived DNA samples (KORA F4 and LBC1936), the
African ancestry cohort with the whole-blood-derived DNA samples (ARIC)
and the cohort of monocyte-derived DNA samples (MESA) of mixed
ancestry (see Table 1). We estimated the proportion of variance in alcohol
consumption explained by a list of CpGs as the difference of adjusted R2-
using a linear regression model that included age, sex and BMI (the ‘Null’
model) and a model that included a list of CpGs in addition to age, sex and
BMI. All selected CpGs were available in MESA and ARIC. Five CpGs in the
144 set and one CpG in the 78 set were unavailable in KORA F4 and
LBC1936 (see Supplementary Table 1). The estimated variance values using
the FHS data are more optimistic compared with those obtained for the
four replication cohorts.
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Epigenome-wide methylation signature of alcohol intake
In the main text, we reported ancestry-stratified meta-analysis
(Po1 × 10− 7) for whole-blood-derived DNA in individuals of EA
(n= 9643) and AA (n= 2423) (Table 1) using an inverse-variance
weighted random-effects model (Figure 1). Meta-analysis of
pooled samples (n= 13 317) and several sensitivity tests including
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Figure 2. A biomarker of heavy alcohol drinking. Four sets of cytosine-phosphate-guanine dinucleotides (CpGs) were selected at s= 0.12
(5 CpGs), s= 0.08 (23 CpGs), s= ‘lambda.1se’ (78 CpGs) and s= ‘lambda.min’ (144 CpGs) using least absolute shrinkage and selection operator
(LASSO) in the Framingham Heart Study (FHS) cohort (the training cohort). ROC analysis was performed to classify heavy drinkers versus non-
drinkers (left figure) and heavy drinkers versus light drinkers (right figure). ‘Non-drinkers’ were subjects with no alcohol consumption (i.e., g
per day= 0); ‘light drinkers’ were subjects who consumed 0og per day⩽ 28 in men and 0og per day⩽ 14 in women; ‘heavy drinkers’ were
subjects who consumed ⩾ 42 g per day in men and ⩾ 28 g per day in women. ARIC, The Atherosclerosis Risk in Communities study; KORA F4,
The Cooperative Health Research in the Region of Augsburg study; LBC1936, The Lothian Birth Cohort 1936; MESA, The Multi-Ethnic Study of
Atherosclerosis.
Table 3. The 30 most significant CpGs in relation to continuous alcohol intake in meta-analysis of whole-blood samples of European ancestry
IlmnID UCSC gene Chr Position P-value β S.e. UCSC CpG islands Relation to UCSC CpG
island
Enhancer
cg03523740 TXLNA 1 32 645 027 4.4E− 15 − 0.00022 2.8E− 05 Chr 1:32 645 154–32 645 814 N_Shore
cg20970369 DENND2D 1 111 744 108 3.2E− 12 − 0.00023 3.3E− 05 Chr 1:111 746 337–111 747 303 N_Shelf
cg16246545 PHGDH 1 120 255 941 1.5E− 12 − 0.00061 8.6E− 05 Chr 1:120 254 844–120 255 499 S_Shore
cg19266329 1 145 456 128 1.7E− 13 − 0.00028 3.8E− 05 TRUE
cg19238380 LMNA 1 156 093 948 2.2E− 12 − 0.00029 4.2E− 05 TRUE
cg11194994 PEA15 1 160 175 974 7.3E− 15 − 0.00017 2.2E− 05 Chr 1:160 175 132–160 175 702 S_Shore
cg07502661 2 43 398 339 2.6E− 12 − 0.00019 2.7E− 05 Chr 2:43 398 040–43398276 S_Shore
cg00883689 SPTBN1 2 54 802 904 3.2E− 12 − 0.00028 4.1E− 05 TRUE
cg13729116 LETM1 4 1 859 262 6.7E− 18 − 0.00018 2.1E− 05 Chr 4:1 857 065–1 858 887 S_Shore
cg25518868 DIAPH1 5 140 984 057 2.3E− 12 − 0.00012 1.8E− 05 TRUE
cg05593667 6 35 490 744 4.4E− 16 − 0.00025 3.1E− 05
cg20732076 TRERF1 6 42 335 231 1.5E− 12 − 0.00015 2.1E− 05 TRUE
cg06189038 GAL3ST4 7 99 767 134 4.6E− 13 − 0.00016 2.2E− 05 Chr 7:99 768 884–99 769 559 N_Shore
cg12873476 8 142 402 728 2.8E− 12 − 0.00023 3.3E− 05 Chr 8:142 401 533− 142 402 494 S_Shore TRUE
cg03599037 C10orf58 10 82 172 508 4.5E− 13 − 0.00014 1.9E− 05 Chr 10:82 168 064–82 168 917 S_Shelf
cg06603309 KCNQ1 11 2 724 144 2.7E− 14 0.00017 2.2E− 05 Chr 11:2 720 410–2 722 087 S_Shelf TRUE
cg11376147 SLC43A1 11 57 261 198 9.8E− 13 − 0.00026 3.6E− 05 TRUE
cg00271311 CNTF 11 58 389 290 1.6E− 13 − 0.00022 2.9E− 05
cg09448652 SNORD30 11 62 621 367 1.3E− 12 − 0.00026 3.6E− 05 Chr 11:62 623 359–62 623 877 N_Shore
cg09737197 CPT1A 11 68 607 675 5.0E− 13 − 0.00016 2.2E− 05 Chr 11:68 608 155–68609419 N_Shore
cg02583484 HNRNPA1 12 54 677 008 1.6E− 19 − 0.00039 4.4E− 05 Chr 12:54 673 322–54 673 550 S_Shelf
cg23654112 TBC1D24 16 2525 928 3.0E− 13 − 0.00014 1.9E− 05 Chr 16:2 521 086–2 525 929 Island
cg08916477 SEPT1 16 30 391 350 4.0E− 13 − 0.00016 2.2E− 05 Chr 16:30 389 035–30 390 631 S_Shore
cg06469895 TERF2 16 69 418 206 1.5E− 13 − 0.00020 2.8E− 05 Chr 16:69 419 316–69 420 086 N_Shore
cg00574412 ABHD15 17 27 892 866 1.1E− 12 − 0.00017 2.3E− 05 Chr 17:27 893 086–27 896 078 N_Shore
cg21626848 SC65 17 39 969 267 3.1E− 15 − 0.00023 2.9E− 05 Chr 17:39 967 407–39 968 604 S_Shore
cg08677210 MSI2 17 55 550 613 3.3E− 12 − 0.00013 1.9E− 05 TRUE
cg15253293 17 79 366 853 1.1E− 15 − 0.00014 1.7E− 05 Chr 17:79 366 806–79374742 Island
cg24217948 SETBP1 18 42 261 980 2.1E− 12 − 0.00028 3.9E− 05 Chr 18:42 258 983–42 260 795 S_Shore TRUE
cg13127741 COMMD7 20 31 331 821 3.1E− 12 − 0.00023 3.3E− 05 Chr 20:31 330 957–31 331 410 S_Shore
Abbreviation: CpG, cytosine-phosphate-guanine dinucleotide; S.e, standard error. Epigenome-wide association and meta-analysis of the continuous alcohol
intake was performed using all whole-blood-derived DNA samples of European ancestry. The DNA methylation proportion was the outcome variable, grams
alcohol consumed per day (g per day) was the predictor variable, adjusting for age, sex, body mass index, technical covariates and white blood cell counts. The
inverse-variance weighted random-effects model was performed in meta-analysis (See Supplementary Table 2 for a full set of significant CpGs). The annotation
“HumanMethylation450_15017482_v.1.2.csv” provided by Illumina was used to annotate the CpG loci.
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EWAS in only drinkers and the investigation of whether or not
prevalent CVD or cancer confound the relationship between DNA
methylation and alcohol consumption are included in the
Supplementary Information.
Genome-wide pattern of DNA methylation associated with alcohol
consumption. We identified hundreds of CpGs (Po1 × 10− 7)
whose differential methylation across the genome was associated
with alcohol intake: 363 CpGs in whole-blood samples of
individuals of EA (Table 3, Figure 3 and Supplementary Table 2),
165 CpGs in whole-blood samples of individuals of
(AA (Supplementary Table 3 and Supplementary Figure 2) and
62 CpGs in monocyte-derived DNA samples (Supplementary Table
4 and Supplementary Figure 3). Additional CpGs at Po1 × 10− 4
are reported in Supplementary Tables 5–7. Genomic inflation in
meta-analysis was estimated at ~ 10% or less, indicating low
additional risk of false-positive findings (Supplementary Table 8).
The majority of the alcohol-related CpGs exhibited an inverse
relationship between higher alcohol intake and lower methylation
(Supplementary Tables 2–4).
Fewer alcohol-related CpGs (Po1 × 10− 7) were identified in the
analysis of the categorical alcohol trait that compared light
drinkers, at-risk drinkers and heavy drinkers with non-drinkers
(Supplementary Tables 9–11 and Supplementary Figures 4–6).
Additional CpGs at Po1 × 10− 4 are included in Supplementary
Tables 12–14. The majority of the alcohol-related CpGs identified
in the analysis of the categorical alcohol trait (Supplementary
Tables 9–11) were also significant or nominally significant in the
association with the continuous alcohol consumption trait
(Supplementary Tables 2–4).
Transethnic replication of methylation signatures
Of the 363 alcohol-related CpGs in EA samples, 56 had Po0.00014
(0.05/363) in AA samples; of the 165 alcohol-related CpGs in AA
samples, 59 had Po0.00030 (0.05/165) in EA samples. Effect
estimates of the 518 (union of 363 and 165) unique CpGs were
moderately correlated between EA and AA whole-blood samples:
Pearson’s correlation r= 0.64 (Figure 4a). For example, cg11376147
in solute carrier family 43 (SLC43A1) displayed Po1 × 10− 7 in both
EA and AA samples from whole blood (Figure 4b).
Methylation signature in whole-blood- and monocyte-derived
DNA
Of the 363 alcohol-related CpGs in EA whole blood samples, 57
replicated (Po0.00014; 0.05/363) in monocyte samples. Of the 62
alcohol-related CpGs in monocytes, 13 replicated (Po0.0008; 0.05/62)
in whole-blood EA samples. The Pearson’s correlation was 0.72 for
the 417 unique (union of 363 and 62) CpGs between EA whole-
blood samples and monocyte samples (Figure 4c). For example,
cg11376147 in SLC43A1 also displayed Po1 × 10− 7 for association
with alcohol consumption in monocyte-derived DNA (Figure 4b).
Similar DNA methylation pattern in former and never drinkers
Based on alcohol consumption at prior examinations in FHS, we
classified the 693 non-drinkers (Table 1) into ‘never’ (n= 107) and
‘former’ drinkers (n= 586). Furthermore, among the 586 ‘former’
drinkers, 91 were ‘former’ heavy drinkers, 66 were ‘former’ at-risk
drinkers and 429 were ‘former’ light drinkers. The EWAS using the
binary trait ‘never’ versus ‘former’ as the independent variable did
Figure 3. Meta-analysis of epigenome-wide association of alcohol intake in European ancestry (EA) whole-blood samples: the Manhattan plot
(top) and the volcano plot (bottom). The DNA methylation proportion was the outcome variable, grams alcohol consumed per day (g per day)
was the predictor variable, adjusting for age, sex, body mass index, technical covariates and white blood cell counts. The inverse-variance
weighted random-effects model was performed in meta-analysis using all whole blood DNA samples of EA.
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not yield any significant results (Supplementary Figure 7). We
compared the EWAS results between ‘heavy’ versus ‘never’ and
‘heavy’ versus ‘former’. For genome-wide methylation loci, the
correlation was 0.32 for regression coefficients and 0.20 for –log10
(P-values); for loci with P–value o1 × 10− 7 (n= 92) in either
‘heavy’ versus ‘never’ or ‘heavy’ versus ‘former’ drinkers, the
correlation was 0.91 for regression coefficients and 0.88 for –log10
(P-values) (Supplementary Figure 8). These results indicate that
DNA methylation levels were not considerably different between
‘never’ drinkers and ‘former’ drinkers and that DNA methylation
changes due to heavy alcohol consumption revert after
individuals abstained from alcohol intake for several years
(FHS examinations were ~ 4 years apart).
Evaluation of smoking in the association between alcohol intake
and DNA methylation
It is unclear if current cigarette smoking confounds the association
between DNA methylation and alcohol intake, or if smoking and
alcohol intake are associated with common CpGs. Therefore, we
performed an analysis using smoking as an additional covariate in
the EWAS (see Materials and methods). We found that some
alcohol-related CpGs displayed a large change (410% change) in
the size of their regression coefficients when smoking was
included as an additional covariate in the analysis of whole-
blood-derived DNA samples in individuals of EA (35 of the 363
CpGs at Po1 × 10− 7) and AA (92 of the 165 CpGs at Po1 × 10− 7)
ancestries, but none of the CpGs in the monocyte-derived DNA
samples changed appreciably after additionally adjusting for
smoking (Supplementary Tables 2–4). Several of the identified
CpGs that displayed a large change in effect estimates following
adjustment for smoking have been previously reported to be
associated with smoking, including the CpGs in the aryl-hydro-
carbon receptor repressor37,38 (Supplementary Tables 5 and 6). We
excluded the 35 CpGs that showed large change in effect estimates
after adjusting for smoking (Supplementary Table 2) in subsequent
analyses that were performed using the whole-blood-derived DNA
samples from individuals of EA ancestry.
Alcohol metabolism enzymes and alcohol-related DNA methylation.
Several functional DNA sequence variants in the alcohol
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) family
of genes are known for their effects on alcohol metabolism.29,30
We checked CpGs in the introns, exons and regulatory regions in
these gene families according to the annotation provided by
Illumina. No CpGs in the ADH (30 CpGs in seven genes) or ALDH
Figure 4. Comparison of regression coefficients of the significant cytosine-phosphate-guanine dinucleotides (CpGs) in association analysis of
the continuous alcohol trait (g per day): (a) between European and African whole-blood samples; (b) the Forest plot of effect estimates and
standard errors of cg11376147 in all study cohorts; and (c) between European whole-blood and CD14+ monocyte samples. (a) Includes a list
of CpGs with Po1 × 10− 7 in EA or AA whole-blood samples and (c) includes a list of CpGs with Po1 × 10− 7 in EA whole-blood samples or in
monocyte samples of mixed ancestries. The Pearson’s correlation was r= 0.64 between the effect estimates in (a) and r= 0.72 in (c). MM,
monocyte, mixed ancestries; WB AA, whole blood, African ancestry; WB EA, whole blood, European ancestry.
Association between DNA methylation and alcohol intake
C Liu et al
430
Molecular Psychiatry (2018), 422 – 433
(340 CpGs in 19 genes) loci were differentially methylated
(Po1 × 10− 7) in relation to alcohol use (Supplementary Tables
5–7, 15, 16).
Neurotransmitter receptors and alcohol-related DNA methylation
γ-aminobutyric acid (GABA), a major neurotransmitter, and its
receptors are known for their involvement in the acute and
chronic behavioral effects of ethanol in humans and animal
models.31–34 A total of 607 CpGs were mapped to introns, exons
and regulatory regions of 22 GABA receptor genes (Supplementary
Table 17). In meta-analysis of whole-blood-derived DNA samples
of EA individuals, cg04781796 (βalcohol = 0.0002, P= 1.9 × 10
− 9) and
cg09577455 (βalcohol =− 0.0015, P= 3.0 × 10
− 8) were significantly
associated with alcohol consumption (Supplementary Table 2).
However, neither of these CpGs was significant in whole-blood-
derived DNA samples of people of AA (cg04781796:
βalcohol = 0.00004, P= 0.17; cg09577455: βalcohol =− 0.00003,
P= 0.0016) or in monocyte-derived DNA samples (cg04781796:
βalcohol = 0.0001, P= 0.22; cg09577455: βalcohol =− 0.00002,
P= 0.82). The CpG cg04781796 is located in a CpG island (Chr 1:
1 959 414–1 959 867, hg19) that is intronic to the GABA-A
receptor, delta (GABRD; Figure 5); and cg09577455 is located in
the north shore of a CpG island (Chr 6: 29 595 298–29 595 795,
hg19) that is intronic to GABA-B receptor subunit 1 (GABBR1, Chr 6;
Supplementary Figure 9). CpG cg04781796 displayed higher
methylation in relation to greater alcohol intake, whereas
cg09577455 displayed lower methylation levels in association
with increased alcohol intake.
Genetic basis underlying the significant alcohol-related CpGs
We tested for association of the methylation levels of 328 CpGs
(selected in meta-analysis of DNA of EA individuals in
Supplementary Table 2) with nearby SNPs (±100KB, cis-SNPs or
cis-meQTLs) in three cohorts (total number of individuals = 4623
from FHS, KORA F4 and PIVUS) (see Materials and methods). A
total of 105 759 SNP-CpG pairs were formed from these 328 CpGs
with cis-SNPs. Meta-analysis of the FHS, KORA F4 and PIVUS
samples identified 14 160 SNP–CpG pairs (170 unique CpGs and
12 857 unique cis-SNPs) at Po0.05/105 759~ 4.7 × 10− 7
(Supplementary Table 18). We found that 16 CpGs had meQTLs
that explained 20–61% of interindividual variance in methylation
at the corresponding CpG (Supplementary Table 18). None of
these 12 857 significant meQTLs was associated with alcohol-
related traits (Po1 × 10− 8) by querying these significant meQTLs
in the Catalog of Published Genome-Wide Association Studies
(http://www.genome.gov/gwastudies/, latest version released on
May 12, 2015).
Association of alcohol-related DNA methylation with gene
expression
We tested for associations between the 328 alcohol-related CpGs
and blood gene expression levels in FHS (n= 1924) and KORA F4
(n= 707) for genes within 1 Mb of these 328 CpGs in both studies
(see Materials and methods). Meta-analysis identified 110 CpG–
gene pairs (83 unique CpGs and 100 unique genes) at Po0.05-
/7111 = 7× 10− 6, where 7111 is the number of tested CpG–gene
pairs (Supplementary Table 19). Of the 110 significant pairs, 86
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Figure 5. The γ-aminobutyric acid-A (GABA-A) receptor, delta (GABRD): the associations of the 36 cytosine-phosphate-guanine dinucleotides
(CpGs) within GABRD, genomic and regulatory features and correlation of methylation measurements. The results were obtained in meta-
analysis of the association analysis of 9643 whole-blood-derived DNA samples of European ancestry (EA) individuals. The correlation of these
36 CpGs was calculated using the methylation measurements at 36 CpGs, adjusting for age, sex, technical covariates and white cell blood
counts in the Framingham Heart Study samples.
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(78%) displayed negative correlations between methylation and
mRNA levels.
We examined associations of the two significant alcohol-related
CpGs in GABA receptor genes with expression of cis genes. At the
GABRD locus, cg04781796 was not associated with expression of
any genes in blood within 1 Mb, whereas cg09577455 in the
GABBR1 locus was associated with the expression of the
interferon-induced transmembrane protein 4 pseudogene
(IFITM4P; P= 2.4 × 10− 6) (Supplementary Table 19). Owing to the
important role of GABA receptors in alcohol-induced signal
transduction and immune functions, we carried out additional
association analyses between these two CpGs and gene
transcripts beyond 1 Mb or on different chromosomes (i.e. trans
associations) in both FHS and KORA F4. Of the 35 746 association
pairs, 228 showed significant association (Po0.05-
/35 746~ 1.4 × 10− 6) with methylation of cg04781796
(Supplementary Table 20) and 13 transcripts were associated with
cg09577455 (Supplementary Table 21) in the meta-analysis.
Functional inference and pathway analysis
Genomic features of the alcohol-related CpGs. We found that the
328 alcohol-related CpG set was significantly enriched for CpG
island shores (48% versus 24%, P= 7.3 × 10− 12) and enhancers
(29% versus 22%, P= 0.003) compared with all CpGs that passed
QC in meta-analysis. In contrast, the 328 alcohol-associated CpG
set was significantly depleted for CpG islands (16% versus 32%,
P= 1.1 × 10− 6) and promoters (3% versus 7%; P= 0.009)
(Supplementary Table 22). There was no significant difference in
proportions of CpG island shelves and DNase I hypersensitive sites
among the 328 alcohol-associated CpGs.
We found similar enrichment and depletion for the 144 CpGs
that were selected in biomarker analysis. These 144 CpGs were
significantly enriched for CpG island shores (47% versus 24%,
P= 4.5 × 10− 11) and enhancers (30% versus 22%, P= 0.002), but
significantly depleted for CpG islands (13% versus 32%,
P= 1.0 × 10− 6) and promoters (2% versus 7%, P= 0.007).
Gene ontology enrichment analysis and functional inference.
A total of 257 genes were annotated to the 328 alcohol-related CpGs.
These 257 genes were enriched for 95 biological processes
(Bonferroni-corrected Po0.05, Supplementary Table 23) including
regulation of transcription, macromolecule metabolic process and
cellular response to stress and chemicals. The most significant
biological process constituted 32 genes enriched (44-fold) for
‘negative regulation of transcription from RNA polymerase II
promoter’ (Bonferroni-corrected P=2.3×10−7; Supplementary Table
24). For the 100 cis genes whose transcript levels were significantly
associated with 83 CpGs (Supplementary Table 19), the analysis of
biological processes showed that the most significantly enriched
process was ‘negative regulation of transposition’ (Bonferroni-
corrected P=8.0×10−4, Supplementary Table 25). Other enriched
processes included defense response to virus (P=0.006) and DNA
cytosine deamination (P=0.02). The trans-transcripts that were
significantly associated with cg04781796 (GABRD) were enriched for
pathways that are involved in immune functions such as lymphocyte
activation (P=1.1×10−11) and immune system process
(P=3.2×10−11; Supplementary Table 26). The trans-transcripts that
were associated with cg09577455 in GABBR1 were also enriched for
immune response (P=0.015; Supplementary Table 27).
DISCUSSION
We conducted an EWAS of alcohol intake in 13 cohorts including
13 317 samples of whole-blood or monocyte-derived DNA from
individuals of mostly EA and AA. We identified hundreds of
differentially methylated CpGs (Po1 × 10− 7) in relation to alcohol
consumption. More than half of the alcohol-related methylation
sites were associated with cis-genetic variants, supporting the
hypothesis that DNA methylation sites are sensitive to both
environmental and genetic influences.39 In addition, we developed
a robust and replicable DNA methylation biomarker that provides
substantial discrimination for current heavy alcohol intake.
A set of 144 CpGs was highly predictive for discriminating
current heavy alcohol drinkers from non-drinkers (AUC40.90) in
all replication cohorts. As a biomarker, these selected CpGs
performed better than commonly clinical variables and biomar-
kers in discriminating current heavy alcohol drinking.7 This is in
line with the discriminatory power of DNA methylation for other
complex traits, such as BMI.40 Therefore, a whole-blood DNA
methylation biomarker has the potential to be developed into a
commercially marketable diagnostic test to detect current heavy
alcohol consumption. Such a test could be useful to supplement
and validate self-reported alcohol consumption data, or in a
forensic setting, or as a screening test.
The biomarker analysis and ancestry-stratified meta-analysis
showed that a number of DNA methylation sites displayed
consistent alcohol-related effects in whole-blood samples of
people of EA and AA. However, the transancestry comparison
also showed the lack of similarities of many CpG sites. We propose
three explanations. First, some DNA methylation sites are truly
ancestry-specific, which needs to be confirmed by future studies.
Second, sample heterogeneity in alcohol consumption may
explain a part of the non-concordance for some CpGs in AA and
EA groups. For example, in ARIC, ~ 76% individuals were non-
drinkers and ~ 17% were heavy drinkers, whereas in most EA
cohorts, 460% of participants were light drinkers. Third, a large
difference in sample sizes (EA n= 9643 and AA n= 2423) and the
probability in sampling are additional reasons for the lack of
replication when a Bonferroni-corrected threshold was used.
We provide evidence that alcohol-related DNA methylation is
associated with gene expression in whole blood. Of note, we
showed that whole-blood epigenetic changes in GABA receptor
genes were significantly associated with the expression levels of a
number of genes that are involved in immune function supporting
the recent findings that GABA and its receptor have effects on
immune cells through cross-talk between the nervous system and
the immune system.41 However, as our data are cross-sectional and
observational in nature, further research is needed to determine if
these changes are causal or reactive. The gene set analysis is based
on a crucial and unrealistic independence assumption pertaining to
genes, which may not be valid for biological processes. Therefore,
we should interpret the significant P-values with caution.42
In addition to the cross-sectional nature of this study, our
findings were limited to DNA samples from mostly middle- and
older-aged individuals of EA and AAs. Future studies are needed
to investigate the generalizability of our findings to other age
groups and ancestries. Nevertheless, as the largest study of its
kind, this work identified a robust alcohol-related DNA methylation
signature in blood and demonstrated that the alcohol-related
methylation changes in blood are of sufficient magnitude to be
interesting clinically, which addresses a gap within the field. Future
studies are warranted to investigate whether alcohol-related
methylation in blood affects GABA neurotransmitter function in
the brain and to investigate how alcohol-related epigenetic
modifications influence the beneficial and detrimental downstream
consequences of alcohol-related health outcomes. Identifying how
alcohol-induced DNA methylation changes modify gene expression
and result in pathway activation or suppression may shed light on
the molecular basis of alcohol addiction and alcohol-related
diseases and reveal new therapeutic strategies.
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